Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease.

Pasala T, Hoo JS, Lockhart MK, Waheed R, Sengodan P, Alexander J, Gandhi S.

Tex Heart Inst J. 2016 Dec 1;43(6):482-487. doi: 10.14503/THIJ-14-4986. eCollection 2016 Dec.

2.

Establishing a predictive model for aspirin resistance in elderly Chinese patients with chronic cardiovascular disease.

Cao J, Hao WJ, Gao LG, Chen TM, Liu L, Sun YF, Hu GL, Hu YX, Fan L.

J Geriatr Cardiol. 2016 Jul;13(5):458-64. doi: 10.11909/j.issn.1671-5411.2016.05.003.

3.

Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists┬┤-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.

Gremmel T, Koppensteiner R, Panzer S.

PLoS One. 2015 Jun 9;10(6):e0129666. doi: 10.1371/journal.pone.0129666. eCollection 2015.

4.

Overcoming aspirin resistance with loading clopidogrel earlier in elective percutaneous coronary intervention.

Ozcan OU, Tutar E, Candemir B, Ustun EE, Erol C.

Int J Angiol. 2015 Mar;24(1):19-24. doi: 10.1055/s-0034-1395981.

5.

Intracoronary adenosine to prevent myonecrosis in patients with stable angina undergoing percutaneous interventions: a double-blinded randomized controlled trial.

Sanati HR, Ghanavati R, Zahedmehr A, Shakerian F, Bakhshandeh H, Firouzi A, Kiani R.

J Tehran Heart Cent. 2013 Jan;8(1):28-34. Epub 2013 Jan 8.

6.

Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban.

Campo G, Fileti L, Valgimigli M, Marchesini J, Scalone A, Ferrari R.

J Blood Med. 2010;1:61-9. doi: 10.2147/JBM.S7236. Epub 2010 May 10.

7.

A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention.

Kim BK, Oh SJ, Yoon SJ, Jeon DW, Ko YG, Yang JY.

Yonsei Med J. 2011 Sep;52(5):717-26. doi: 10.3349/ymj.2011.52.5.717.

8.

Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.

Sambu N, Curzen N.

Br J Clin Pharmacol. 2011 Oct;72(4):683-96. doi: 10.1111/j.1365-2125.2011.03955.x. Review.

9.

Effect of glucose or fat challenge on aspirin resistance in diabetes.

Yassine HN, Davis-Gorman G, Stump CS, Thomson SS, Peterson J, McDonagh PF.

Int J Endocrinol. 2010;2010:820876. doi: 10.1155/2010/820876. Epub 2011 Jan 26.

10.

Aspirin resistance: Fact or fiction? A point of view.

Mehta JL, Mohandas B.

World J Cardiol. 2010 Sep 26;2(9):280-8. doi: 10.4330/wjc.v2.i9.280.

11.

Clinical determinants of aspirin resistance in diabetes.

Yassine HN, Davis-Gorman G, Stump CS, Thomson SS, Peterson J, McDonagh PF.

Diabetes Res Clin Pract. 2010 Oct;90(1):e19-21. doi: 10.1016/j.diabres.2010.07.008. Epub 2010 Aug 16.

12.

Antiplatelet Resistance-Does it Exist and How to Measure it?

Saraf S, Bensalha I, Gorog DA.

Clin Med Cardiol. 2009 Sep 3;3:77-91.

13.

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.

Sharma RK, Reddy HK, Singh VN, Sharma R, Voelker DJ, Bhatt G.

Vasc Health Risk Manag. 2009;5:965-72. Epub 2009 Nov 16. Review.

14.

Aspirin resistance.

Mansour K, Taher AT, Musallam KM, Alam S.

Adv Hematol. 2009;2009:937352. doi: 10.1155/2009/937352. Epub 2009 Apr 14.

15.

Aspirin and clopidogrel response variability: review of the published literature.

Ferguson AD, Dokainish H, Lakkis N.

Tex Heart Inst J. 2008;35(3):313-20. Review.

16.

Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease.

Muir AR, McMullin MF, Patterson C, McKeown PP.

Heart. 2009 Aug;95(15):1225-9. doi: 10.1136/hrt.2008.150631. Epub 2008 Aug 12.

17.

Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y(1) and the P2Y (12) receptor and is correlated with protein expression of P2Y (12).

Braun OO, Amisten S, Wihlborg AK, Hunting K, Nilsson D, Erlinge D.

Purinergic Signal. 2007 Jun;3(3):195-201. doi: 10.1007/s11302-006-9028-9. Epub 2006 Nov 30.

18.

Point-of-care platelet function testing in patients undergoing PCI: between a rock and a hard place.

van Werkum JW, Hackeng CM, de Korte FI, Verheugt FW, Ten Berg JM.

Neth Heart J. 2007;15(9):299-305.

19.
20.

Measurement and prevention of myocardial injury during percutaneous coronary intervention.

Schiano P, Gabriel Steg P.

Heart. 2007 Jun;93(6):656-7. No abstract available.

Supplemental Content

Support Center